Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21860724 | 0.86 | CYP19A1 (0.44) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL21860763 | 0.84 | CYP19A1 (0.57) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL21860725 | 0.82 | CYP19A1 (0.55) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL21860520 | 0.82 | CYP19A1 (0.55) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL21860987 | 0.82 | CYP19A1 (0.48) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL21860981 | 0.79 | CYP19A1 (0.41) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL21834848 | 0.77 | CYP19A1 (0.63) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Hydrochloric Acid SCHEMBL30828421 | 0.76 | CYP19A1 (0.61) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Hydrochloric Acid SCHEMBL30828447 | 0.76 | CYP19A1 (0.61) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL29277156 | 0.73 | CYP19A1 (0.57) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | SEIKAGAKU CORPORATION (JP) | 2022-02-10 | — | — | US | disclosed |
| WO-2020067507-A1 | PRIMARY AMINE COMPOUND- OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE, AND METHOD FOR PRODUCING SAME | 生化学工業株式会社 | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040318-A1 | PRIMARY AMINE COMPOUND OR SECONDARY AMINE COMPOUND-ACIDIC POLYSACCHARIDE CONJUGATE AND PRODUCTION METHOD THEREFOR | ALG1, NGLY1, SAT1 | CYP19A1 2146/4885CYP3A4 3231/4885CYP17A1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.